In the PR, MM said this, “The overall survival data for cabozantinib from the METEOR trial represent an important milestone in the treatment of advanced renal cell carcinoma. When taken alongside data from the trial’s other endpoints, this result makes cabozantinib the first therapy to demonstrate improvements in the three key measures of efficacy in a large randomized phase 3 trial of patients with this advanced form of cancer."
From the original release of the 'stat-sig' statement, and the months leading up to this, they have certainly set expectations. It'd be inexplicable to make this statement above, and then announce uninspiring OS results, IMO. EXEL has given us all blue balls....Hoping for some 'relief'.
Treats NASH liver disease. Gilead under pressure to increase its 'liver' pipeline to supplement its waning hepatitis drug. The Nimbus drug is not even out of phase II yet. Paid $400 million. Hmmm. Looking to expand its liver pipeline .......
I feel your pain but with all due respect, and I mean that, and not that I have to defend Ernie (God knows he's attempted to spank me a few times), but I will say if nothing else he's transparent. And he trades, even though I believe his long term bias is long. I like hearing the analyses of traders (including short traders). They don't have blinders on. So as long as you know that, you take all that into consideration when you digest there calls/analysis. My stupid opinion anyway...Good luck. I'm hanging in there with you, too long for too long. LOL!
An 'Infrastructure Engineer' is simply a relatively low level IT position. They are saying they need someone (every organization does) to install IT (information Technology) systems that support e-mail, HR systems, maybe an ERP system. And its very likely that much of the IT Infrastructure (think hardware and software) would be implemented in the cloud with very little actual hardware on premise anyway. This person would report to a CTO, or Director of Infrastructure, or a CIO, etc. Its a worker bee position. Don't get confused witt the "Engineer" part of the title. They may be replacing someone, but as important a function as this position may be, these guys are a dime a dozen. This is my business, so my 2 cents..
Mostly directed to Ernie.
First your explanations, analysis, your rationale for your recent transactions were excellent as always and like most here I enjoy reading them. But most recently there was a long thread regarding the SP itself and most lamenting why after all this news (since August) and especially the JV announcement and details it still languishes. Your (and others here) all had provided a great expose on the convertible debt and the eventual bills coming due in the next several years. OK, I get it. But when you sold at $5.30 in December, the issue associated with the converts and the debt was in place back then too. At the time you lamented the lack of a JV deal among other things and the possible need for a secondary because of it. . So fast forward less than 3 months later, they have that deal. There is much more clarity regarding their finances, great OS results, another JV coming for Japan. Compared to December the state of EXEL is much clearer, and a whole lot better. 'Logic' would say, hey the SP should now reflect all this. Like I said, the Convert issue never went away, and in so many ways, EXEL is in a much better shape. What has changed that dramatically from December that could possibly explain the current languishing SP down over 30%? Anyone?
Go to IPSEY stock quote and look at recent news articles (wouldnt allow me to cut and paste). There is a Jan 16th story about how Ipsen realized they need to get aggressively into the cancer market and needed to make deals. Went to JP Morgan Chase conference recently in SF looking to talk up partners. They have cash up the ying yang and were motivated to get in the cancer market. Good for EXEL.
Thank you friend. I said it tongue in cheek and hoping I didn't say it too early. This stock has its moments after all. Would love to hear you did jumped in. If not jump in tomorrow. Hopefully plenty of upside ahead.
A few weeks ago, seemingly minutes after EXEL releases the OS news on METEOR, AF published an article that one can argue had all intentions to simply undermine the good news. It was released so quickly it was if he had it pre-written with his finger on the publish button waiting on the EXEL PR. So how about it AF, how about an 'attaboy' for your butt boy EXEL?
Let me know when you jump in. Swim over to the deep side. That's where you'll find me. Under water, gasping for air, grasping at the legs of Anyone (everyone) above me.
Ok. Considering I jumped in late yesterday for another 5K of this POS, now at 65K, here's hoping you are a proverbial Radar O'Reily. Pray for me, LONSL (Laughing out not so loud).
I S*** you not but this comes right out of a newswire..
Co today announced that it received yesterday evening a Refuse to File letter from the FDA regarding PTC's New Drug Application for Translarna (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense
Wow..It would be blockbuster for this board if it ever got to market:)
Just an FYI but Accountemps was not referring to EXEL, rather PTC Therapeutics...
"Shares of PTC Therapeutics Inc. PTCT, -61.61% fell more than 35% following news the company received a refuse to file letter from the U.S. Food and Drug Administration for a new drug, Translarna. The FDA, according to a news release, said the application for Trnaslarna was not up to standards in order to permit a substantive review."
"It would be interesting to see if the offers they are looking at now are better or worse than what may have been on the table 2 years ago"
Or is it in the realm of consideration that there were no serious offers back then based on the emergence of Opdivo which was always slightly ahead of the development curve (I'm assuming), or otherwise an emerging competitive drug? In other words, why partner if CABO wouldn't be competitive? So they wait for the empirical evidence, PFS and OS and whatever else. And that is what these partners are looking at now, and why they (actual OS numbers) have not been released publically..
Timing is poor for EXEL in this regard as the final report card for CABO is bumping up against the cash issue. Whatever 'additional' value could be attributed to CABO from the apparent exceptional OS numbers from a negotiation standpoint for EXEL, are somewhat (or greatly) diminished by EXELs need to do a deal to avoid the impending cash issue.
Any validity to that possible scenario?
before you go.. "I guess if I were going to do a deal I would wait until there is actually a product to peddle. Then I could gauge what it is worth" I have been saying this for some time now. And the 'non-release' of those 'super fantastic' OS numbers also raises eyebrows. I think the success of Opdivo has made a JV deal riskier for the partner. They now want to see an approved product, to your point, and due to the now more competitive landscape, they want to know it can compete, hence the OS numbers. I believe more and more that by NOT releasing the numbers, they keep BMY/Opdivo a bit in the dark, while they show them to their potential JV partners. I gave you a thumbs up and now for the first time ever you have twice as many thumbs up as down. You are Ray Romano!! LoL
Homeslice, only 5 thumbs down. Wow, you must be growing on some. Hope all is well. My prediction is a JV before a secondary is needed. I guess I should say my hope is a JV before a secondary. Sigh...